Record date is 31 May 2017
The Management Committee of Board of Directors of amalgamated entity i.e. Dishman Carbogen Amcis ('DCAL') [formerly known as Carbogen Amcis (India)], in its meeting held on 19 May 2017, has fixed 31 May, 2017 as the Record Date for the purpose of deciding the members who shall be eligible for allotment of equity shares of the amalgamated entity, Dishman Carbogen Amcis to the shareholders of erstwhile Dishman Pharmaceuticals and Chemicals ('DPCL') in the ratio of 1:1 i.e. Share Exchange Ratio [1 (One) fully paid-up Equity Share of Rs.2/- (Rupees Two only) each of DCAL, for every 1 (One) fully paid-up Equity Share of Rs.2/- (Rupees Two only) each held by such shareholder in DPCL], fixed under the Scheme of Arrangement and Amalgamation approved by the Hon'ble High Court of Gujarat.Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
